Details of the Drug-Related molecule(s) Interaction Atlas

General Information of DTT (ID: TTBHFYQ)

• DTT Name: Mucin-1 (MUC1) DTT Info
• Gene Name: MUC1

Molecule-Related Drug & Molecule List

24 Clinical Trial Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Yttrium (90Y) clivatuzumab tetraxetan	DMOLR5W	Pancreatic cancer	2C10	Phase 3	[1]
TG-4010	DMWE3GB	Bipolar disorder	6A60	Phase 2/3	[2]
AS-1402	DMMX1EJ	Breast cancer	2C60-2C65	Phase 2	[3]
Emepepimut-S	DMCLT2F	Non-small-cell lung cancer	2C25.Y	Phase 2	[4]
GO-203-2c	DMLWKZ7	Acute myeloid leukaemia	2A60	Phase 2	[5]
ICO-25	DMC13BQ	Breast cancer	2C60-2C65	Phase 2	[6]
MUC1-Poly-ICLC	DML7N4B	Colorectal cancer	2B91.Z	Phase 2	[7]
Pankomab-GEX	DMAZ460	Solid tumour/cancer	2A00-2F9Z	Phase 2	[8]
SAR-566658	DMT4FI5	Triple negative breast cancer	2C60-2C65	Phase 2	[9]
Anti-MUC1 CAR T Cells	DM0C1IX	Breast cancer	2C60-2C65	Phase 1/2	[10]
Anti-MUC1 CAR-T cells	DMTQIB2	Colorectal cancer	2B91.Z	Phase 1/2	[11]
BrevaRex	DMCEGP2	Pancreatic cancer	2C10	Phase 1/2	[12]
CAR-T cells targeting Muc1	DM5FKU1	Cervical cancer	2C77.0	Phase 1/2	[13]
CAR-T cells targeting MucI	DMBPN4K	Lung cancer	2C25.0	Phase 1/2	[14]
G0-203-2c	DMG48WN	Pancreatic cancer	2C10	Phase 1/2	[5]
ImMucin	DM09JOZ	Multiple myeloma	2A83	Phase 1/2	[15]
MUC-1 CART cell immunotherapy	DMFUDHM	Intrahepatic cholangiocarcinoma	2C12.10	Phase 1/2	[16]
Muc1-specific gene-engineered T cells	DMPNR0J	Acute myeloid leukaemia	2A60	Phase 1/2	[17]
Anti-MUC1 mab	DMQ5ZND	Pancreatic cancer	2C10	Phase 1	[18]
CART-Muc1 cells	DMOJEXG	Acute myeloid leukaemia	2A60	Phase 1	[19]
HuMNC2-CAR44 T cells	DMVGBA1	Breast cancer	2C60-2C65	Phase 1	[20]
MUC-1 dendritic cancer vaccine	DMG4QDT	Solid tumour/cancer	2A00-2F9Z	Phase 1	[21]
ONT-10	DMUZFVH	Solid tumour/cancer	2A00-2F9Z	Phase 1	[22]
TnMUC-1 CAR-T cell therapy	DMHD6PA	Solid tumour/cancer	2A00-2F9Z	Phase 1	[23]

1 Preclinical Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
CAR-T cells targeting Mucl	DMA1BLC	Acute myeloid leukaemia	2A60	Preclinical	[24]

1 Investigative Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
TG-1031	DM5VJQP	Discovery agent	N.A.	Investigative	[25]

References

• [1] Clinical pipeline report, company report or official report of Immunomedics.
• [2] A phase II study of Tg4010 (Mva-Muc1-Il2) in association with chemotherapy in patients with stage III/IV Non-small cell lung cancer. J Thorac Oncol. 2008 Jul;3(7):735-44.
• [3] Phase I dose escalation pharmacokinetic assessment of intravenous humanized anti-MUC1 antibody AS1402 in patients with advanced breast cancer. Breast Cancer Res. 2009;11(5):R73.
• [4] Emepepimut-S for non-small cell lung cancer. Expert Opin Biol Ther. 2011 Aug;11(8):1091-7.
• [5] Clinical pipeline report, company report or official report of Genus Oncology.
• [6] The role of epithelial antigens in diagnosis and staging of breast cancer. Arkh Patol. 2002 Nov-Dec;64(6):13-5.
• [7] Early in vivo signaling profiles in MUC1-specific CD4+ T cells responding to two different MUC1-targeting vaccines in two different microenvironments. Oncoimmunology. 2013 Mar 1;2(3):e23429.
• [8] Staining of MUC1 in ovarian cancer tissues with PankoMab-GEX detecting the tumour-associated epitope, TA-MUC1, as compared to antibodies HMFG-1 and 115D8. Histol Histopathol. 2013 Feb;28(2):239-44.
• [9] Integrating in vitro signaling and drug response data from single cell network profiling (SCNP) to inform on individual's AML biology.Molecular Cancer Therapeutics. 11/2011; 10(Supplement 1):A73-A73.
• [10] ClinicalTrials.gov (NCT02587689) Phase I/II Study of Anti-Mucin1 (MUC1) CAR T Cells for Patients With MUC1+ Advanced Refractory Solid Tumor
• [11] ClinicalTrials.gov (NCT02617134) CAR-T Cell Immunotherapy in MUC1 Positive Solid Tumor
• [12] Phase I trial of a murine antibody to MUC1 in patients with metastatic cancer: evidence for the activation of humoral and cellular antitumor immunity. Ann Oncol. 2004 Dec;15(12):1825-33.
• [13] ClinicalTrials.gov (NCT03198052) HER2/Mesothelin/Lewis-Y/PSCA/MUC1/PD-L1/CD80/86-CAR-T Cells Immunotherapy Against Cancers
• [14] ClinicalTrials.gov (NCT03267173) Evaluate the Safety and Efficacy of CAR-T in the Treatment of Pancreatic Cancer.
• [15] Phase I/II study exploring ImMucin, a pan-major histocompatibility complex, anti-MUC1 signal peptide vaccine, in multiple myeloma patients. Br J Haematol. 2015 Apr;169(1):44-56.
• [16] ClinicalTrials.gov (NCT03633773) Safety and Efficacy Evaluation of MUC-1 CART in the Treatment of Intrahepatic Cholangiocarcinoma
• [17] ClinicalTrials.gov (NCT03222674) Multi-CAR T Cell Therapy for Acute Myeloid Leukemia
• [18] Characterization of an anti-MUC1 monoclonal antibody with potential as a cancer vaccine. Hybrid Hybridomics. 2001;20(5-6):313-24.
• [19] ClinicalTrials.gov (NCT03291444) CAR-T Cells Combined With Peptide Specific Dendritic Cell in Relapsed/Refractory Leukemia/MDS
• [20] Clinical pipeline report, company report or official report of Minerva Biotechnologies.
• [21] Dendritic cell vaccine immunotherapy of cancer targeting MUC1 mucin. Int J Mol Med. 2003 Oct;12(4):493-502.
• [22] Clinical pipeline report, company report or official report of Oncothyreon.
• [23] ClinicalTrials.gov (NCT04025216) A Study of CART-TnMUC1 in Patients With TnMUC1-Positive Advanced Cancers. U.S. National Institutes of Health.
• [24] ClinicalTrials.gov (NCT03473457) CAR-T Cells Therapy in Relapsed/Refractory Acute Myeloid Leukemia
• [25] Technology evaluation: TG-1031, Transgene SA.Curr Opin Mol Ther.2000 Feb;2(1):106-11.